Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone vs Quetiapine in Chronic Schizophrenia (PEARL 3 Extension)
NCT00789698Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2008
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of lurasidone in schizophrenia (2 arms), sponsored by Sumitomo Pharma America. Primary endpoint: Relapse of Psychotic Symptoms at 12 months. Started Dec 2008; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00789698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00789698.